Moderna, Inc. (NASDAQ: MRNA) saw a sharp rise in investor attention on 9 May 2026. The Company’s shares surged 18.6% to US$57.55, reaching a two-month high, after its early-stage mRNA hantavirus vaccine research came into public focus. Including the day’s gains, Moderna stock has nearly doubled year-to-date.
Figure 1: Moderna signage at the Company’s office [Courtesy: Pharmaceutical Technology]
Trading volume on the day surged to more than 12 million shares by Friday afternoon. That figure is approximately double the 25-day moving average of 5.77 million shares.
The Moderna stock price surge reflects renewed confidence in the Company’s ability to extend its mRNA platform beyond COVID-19 vaccines.
Moderna and Korea University: The Research Collaboration Behind the Move
The renewed market focus centres on a research agreement Moderna signed in September 2023 with the Vaccine Innovation Center at Korea University College of Medicine (VIC-K).
The deal was struck under Moderna’s mRNA Access initiative, a programme that supplies preclinical mRNA vaccine candidates to academic teams working on emerging or neglected infectious diseases.
Moderna confirmed the collaboration through a spokesperson, describing it as part of its mRNA Access Program, which supports external research on viruses of concern in advance of potential outbreaks.
The Company characterised the efforts as early-stage and ongoing, reflecting its broader responsibility to develop countermeasures against emerging infectious diseases.
What the mRNA Access Program Involves
The Vaccine Innovation Center will use preclinical mRNA vaccine candidates provided by Moderna under the mRNA Access Program to develop a hantavirus vaccine effective against a broader range of virus strains than existing vaccines.
Moderna’s Chief Medical Officer Francesca Ceddia, stated that the partnership is expected to strengthen mRNA vaccine research and development capabilities in Korea and bring significant advancements in public health.
VIC-K Director Heejin Cheong described it as meaningful to continue the legacy of the late Professor Ho Wang Lee, who first isolated the hantavirus and contributed to early vaccine development.
Why Hantavirus Matters as a Research Target
The World Health Organisation has designated hantavirus as a potential “Disease X” pathogen capable of triggering new infectious diseases, underlining the urgency for updated vaccine candidates.
The current commercially available hantavirus vaccine has been in use since 1990, and researchers have identified a clear need to improve both efficacy and strain coverage.
Figure 2: Hantavirus test samples [Courtesy: Reuters]
Mouse experiments have already confirmed the protective efficacy of the mRNA-based hantavirus vaccine candidate developed in collaboration with Moderna. However, funding constraints have blocked human clinical trials from proceeding.
Moderna as a Company: What Investors Are Backing
Moderna is a pioneer and leader in the field of mRNA medicine. Since its founding, the Company’s mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, and rare diseases.
Moderna entered 2026 with three approved products, Spikevax, mNEXSPIKE, and mRESVIA, with seasonal vaccines expected to deliver up to 10% revenue growth in the year ahead.
The hantavirus collaboration sits within a significantly broader pipeline. Moderna holds 41 pipeline candidates as of 2024 to 2026, giving the Company a leading position in clinical-stage mRNA vaccine development spanning infectious diseases, oncology, and rare diseases.
A Platform Built for Speed and Adaptability
Moderna’s mRNA platform enables the rapid design, research, and testing of multiple mRNA sequences within days. The Company’s novel production methods are designed to allow medicines to reach more people at a faster pace than traditional vaccine development approaches.
This adaptability is central to why the Moderna hantavirus vaccine development collaboration attracted investor attention. The mRNA hantavirus vaccine research does not need to start from scratch, it draws on an established platform already proven across multiple disease areas.
Industry Outlook
The global mRNA vaccine research sector is at an inflection point. Moderna enters 2026 with a focus on growing sales, launching new infectious disease products, and delivering pivotal readouts across oncology, rare disease, and infectious disease portfolios.
The Moderna hantavirus vaccine development programme adds to a growing list of mRNA hantavirus vaccine research collaborations aimed at addressing pathogens the WHO has flagged as high-priority outbreak risks.
For markets, the speed at which mRNA platforms can respond to emerging disease threats continues to be a key driver of investor interest in biotech stocks.
Future Direction and Impact on MRNA Investors
The Moderna stock price surge on 9 May 2026 reflects a broader re-rating of the Company’s pipeline value. Key items to watch include:
- The mRNA hantavirus vaccine research with VIC-K remains preclinical and has not yet entered human trials
- Funding constraints at Korea University have delayed the transition to clinical-grade manufacturing, with costs estimated between 10 billion won and 20 billion won
- Moderna’s mRNA Access Program continues to expand globally, providing a low-cost route to early-stage collaboration on emerging disease targets
- The WHO’s classification of hantavirus as a Disease X pathogen increases the strategic value of early-stage mRNA hantavirus vaccine research
- Moderna’s broader pipeline includes 41 candidates across infectious disease, oncology, and rare disease as of early 2026
- The Company targets up to 10% revenue growth in 2026, supported by approved products and new seasonal vaccine launches
- Investors tracking the Moderna stock price surge should note that the hantavirus programme is early-stage and does not represent a near-term commercial catalyst
ALSO READ: St George Mining Appoints Worley to Drive Araxá Feasibility Studies
Frequently Asked Questions
Q1. Why did Moderna stock surge on 9 May 2026?
Ans. Moderna shares jumped 18.6% to US$57.55 after renewed focus on its early-stage mRNA hantavirus vaccine research collaboration with Korea University came into the spotlight.
Q2. What is the Moderna hantavirus vaccine development programme?
Ans. It is a preclinical research collaboration between Moderna and Korea University’s Vaccine Innovation Center, signed in September 2023 under Moderna’s mRNA Access Program.
Q3. Has the hantavirus vaccine entered human trials?
Ans. No. The mRNA hantavirus vaccine research remains preclinical. Funding constraints have delayed the move to clinical-grade manufacturing and human trials.
Q4. What is Moderna’s mRNA Access Program?
Ans. It is Moderna’s public health initiative that provides preclinical mRNA vaccine candidates and technical support to academic researchers working on emerging or neglected infectious diseases.
Q5. What is Moderna’s broader pipeline beyond hantavirus?
Ans. Moderna holds 41 pipeline candidates across infectious disease, oncology, and rare disease as of 2026, including approved products Spikevax, mNEXSPIKE, and mRESVIA.
Disclaimer
This article is intended for informational purposes only and does not constitute financial or investment advice. All content is based on publicly available reporting online. Share price and trading volume data reflect figures provided in the source material at the time of publication. Investing in securities involves risk, including the possible loss of principal. Readers should conduct their own research and seek independent financial advice before making any investment decisions. Colitco does not hold any position in the companies or organisations mentioned.
Sources
- https://au.investing.com/news/stock-market-news/moderna-stock-surges-on-hantavirus-vaccine-development-plans-93CH-4420853
- https://brusselssignal.eu/2026/05/korea-university-and-moderna-have-been-working-on-mrna-hantavirus-vaccine-since-2023/
- https://www.koreabiomed.com/news/articleView.html?idxno=24477
- https://www.eurekalert.org/news-releases/1056868
- https://www.newsweek.com/did-moderna-start-developing-hantavirus-mrna-vaccine-in-2024-what-we-know-11924648
- https://www.modernatx.com/research/product-pipeline
Last modified: May 9, 2026
